Navigation Links
QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy
Date:5/22/2008

surgery and prior to the first 12mg/8mg dose of Q8003IR, the baseline patient pain intensity (PI) scores averaged 6.6 out of 10 units -- with 10 being the most severe on the Numerical Pain Rating Scale. Analgesic effects as reflected in the maximum pain improvement (PI) for the 12mg/8mg dose of Q8003IR yielded a 2 unit reduction of PI (decreasing patient scores to 4.6) versus a 0.14 unit increase of PI for placebo-treated patients. Placebo patients were treated with ibuprofen, a non-opioid analgesic.

The mean time to confirmed perceptible pain relief for Q8003IR was 42 minutes compared to 4.4 hours for placebo. The duration time of analgesic effect was 6.6 hours for Q8003IR versus 2.8 hours for placebo.

The 12mg/8mgdose data demonstrated that Q8003IR was well tolerated, with a low rate of patient withdrawal (8% discontinuing use due to adverse events and 6% discontinuing use due to efficacy failure) compared to placebo (with 2% discontinuing use due to adverse events and 25% discontinuing use for efficacy failure). Only 2% of 12mg/8mg Q8003IR treated patients experienced somnolence, and no incidences of euphoria were reported. The low level of somnolence and absence of euphoria reported were unexpected outcomes compared to what is typically seen with morphine or oxycodone. The significance of these observations will need to be confirmed in future studies that provide a direct data comparison.

All patients exhibited acceptable respiratory rates with reduction in blood oxygen levels occurring in less than 2% of those on the preferred dose of Q8003IR. Typical of opioid drugs, nausea and vomiting were the most common adverse events. Of patients receiving the 12mg/8mg dose, 56% experienced mild to moderate nausea that diminished over the first few hours of treatment; no incidences of severe nausea were reported. 32% of patients reported vomiting with initial dosing (18% mild to moderate and 14% severe). 20% of patients experienced mild to moderate di
'/>"/>

SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
2. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
3. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
4. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
5. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
6. Immunosyn Corporation Releases SF-1019 Study Results
7. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
8. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. announces ... Ltd., has received Chinese FDA (CFDA) approval and ... Tablets into the China ... and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., ... US FDA approved and China CFDA certified oral ...
(Date:8/20/2014)... LOS ANGELES , Aug. 20, 2014   Easy Breathe ... today announced that its " Easy Blog " - has received ... the year.   "We are thrilled that so many ... Nick Weiss , CEO of Easy Breathe. "We,re committed to making ... use Easy Blog to stay informed about sleep apnea news ...
(Date:8/20/2014)... MUMBAI , August 20, 2014 ... owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), ... studies of a novel clinical development candidate, GBR ... discovered and developed by the Glenmark Biologics Research ... . GBR 1302 is based on Glenmark,s ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
... Response Rate and 100% Disease Control Rate Observed in ... Patients with Medullary Thyroid Cancer, CHICAGO, June ... from an ongoing phase 1 clinical trial of,XL184, a novel small ... The maximum tolerated dose (MTD) for,XL184 has been determined to be ...
... Recipients with Cancer, HERSHEY, Pa., June 1 ... cancer is challenging.,Clinicians must balance the need to ... of chemotherapeutic agents on a,patient,s immune system., ... will be,presented today at the American Transplant Congress ...
Cached Medicine Technology:Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity 2
(Date:8/21/2014)... (PRWEB) August 21, 2014 While golfing ... found it hard to stay focused on his game ... mosquitoes. The constant whine, slapping and continual need to ... innovative methods to stay protected from insects while golfing. ... career in the Financial Services/Investment Banking Industry, decided to ...
(Date:8/21/2014)... 21, 2014 Denver marketing agency ... for the American Lung Association in Colorado’s 2014 ... welcome Webolutions as a sponsor,” said Curt Huber, Chief ... Executive Director, American Lung Association in Colorado, “and we’re ... in this role they’ve defined.” , Webolutions has also ...
(Date:8/21/2014)... August 21, 2014 HIPAA Secure Now! ... making it possible for EHR vendors to now offer ... requirement for achieving meaningful use. , HIPAA Secure ... to medical practices throughout the U.S. The company assesses ... information (ePHI) from each system and device used by ...
(Date:8/21/2014)... Consilium Staffing, Your Partner in Locum Tenens, ... in response to the President’s landmark VA hospital reform ... the Department of Veterans Affairs to hire more doctors. ... one hundred fifty medical centers nationwide, and has been ... awaiting treatment, including vets from the Vietnam War, Iraq, ...
(Date:8/21/2014)... PA (PRWEB) August 21, 2014 The ... Crossing Historic Park in Washington Crossing, Pennsylvania on Thursday, ... the park. “We have been looking for different ways ... said Matt Kiernan, Partner with Pharmica Consulting. “When we ... part of U.S. history, we jumped at the opportunity.” ...
Breaking Medicine News(10 mins):Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:HIPAA Secure Now! Ramps up EHR Partner Program, Helps Healthcare Providers Achieve Meaningful Use under Revised CMS Deadlines 2Health News:Consilium Staffing Providing Locum Tenens in Response to VA Hospital Reform Legislation 2Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2
... Women,s Health Study Reveals that Strawberries May Help Reduce ... Having Elevated Inflammation in ... are not only,delicious and nutrient-rich, new research from Harvard ... The new study found,that those who reported eating the ...
... Up-Time and Improved Overall ... Laboratory ... (http://www.siemens.com/diagnostics ) announced today,worldwide availability of version 2.0 software ... will be a required upgrade for,all existing customers and included ...
... stepping into the national limelight with the establishment ... Research., The new center, funded by a $10 ... Health (NIMH), will support interdisciplinary studies aimed at ... in the brain., The neurotransmitter serotonin is central ...
... Inc. (NYSE: MYL ),today announced the appointment ... of Global Technical Operations. Mr. Malik has served ... acquired a controlling stake in Matrix,Laboratories Limited (Matrix), ... As Head of Global Technical Operations, Mr. ...
... Inc. (NYSE: MYL ),today announced the appointment of ... East and Africa) following the completion,of Mylan,s acquisition of ... Barret most recently served as Region Director,EMEA, reporting to ... 2004,following his role as Area Director for Southern Europe, ...
... disease care, study finds , , TUESDAY, Oct. 2 (HealthDay ... rates of chronic disease in the United States, with ... a new study finds. , It,s an expensive problem, ... and heart disease account for some $100 to $150 ...
Cached Medicine News:Health News:Strawberry Consumption Associated with C-Reactive Protein Among Women: New Harvard Study 2Health News:Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software 2Health News:Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software 3Health News:Vanderbilt nets brain gene research center 2Health News:Vanderbilt nets brain gene research center 3Health News:Mylan Appoints Rajiv Malik as Executive Vice President, Head of Global Technical Operations 2Health News:Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa 2Health News:Obesity Driving Rising U.S. Health Costs 2Health News:Obesity Driving Rising U.S. Health Costs 3
This instrument measures intraocular pressure without,contacting. Alignment is performed semi-automatically....
... InfusO.R. Pump is a syringe ... in the administration of many ... procedures. It provides for the ... relaxants, and vasoactive drugs through ...
... Management System answers the day-to-day needs ... flexibility. From programming to data retrieval, ... management right where you want it. ... to help each patient become ambulatory ...
The FLO-GARD 6201 Volumetric Infusion Pump and the FLO-GARD 6301 Dual-Channel Volumetric Infusion Pump are industry standard in standard set infusion pump technology....
Medicine Products: